Download PDF
Semin Thromb Hemost 2014; 40(07): 756-765
DOI: 10.1055/s-0034-1381233
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?

Giuseppe Lippi
1   Laboratory of Clinical Chemistry and Hematology, Academic Hospital of Parma, Parma, Italy
,
Emmanuel J. Favaloro
2   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, Westmead, New South Wales, Australia
,
Camilla Mattiuzzi
3   Service of Service of Clinical Governance, General Hospital of Trento, Trento, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2014 (online)

    Permissions and Reprints

Abstract

The recent development and marketing of novel direct oral anticoagulants (DOACs) represents a paradigm shift in the management of patients requiring long-term anticoagulation. The advantages of these compounds over traditional therapy with vitamin K antagonists include a reportedly lower risk of severe hemorrhages and the limited need for laboratory measurements. However, there are several scenarios in which testing should be applied. The potential for drug-to-drug interaction is one plausible but currently underrecognized indication for laboratory assessment of the anticoagulant effect of DOACs. In particular, substantial concern has been raised during Phase I studies regarding the potential interaction of these drugs with some antibiotics, especially those that interplay with permeability glycoprotein (P-gp) and cytochrome 3A4 (CYP3A4). A specific electronic search on clinical trials published so far confirms that clarithromycin and rifampicin significantly impair the bioavailability of dabigatran, whereas clarithromycin, erythromycin, fluconazole, and ketoconazole alter the metabolism of rivaroxaban in vivo. Because of their more recent development, no published data were found for apixaban and edoxaban, or for potential interactions of DOACs with other and widely used antibiotics. It is noteworthy, however, that an online resource based on Food and Drug Administration and social media information, reports several hemorrhagic and thrombotic events in patients simultaneously taking dabigatran and some commonly used antibiotics such as amoxicillin, cephalosporin, and metronidazole. According to these reports, the administration of antibiotics in patients undergoing therapy with DOACs would seem to require accurate evaluation as to whether dose adjustments (personalized or antibiotic class driven) of the anticoagulant drug may be advisable. This might be facilitated by direct laboratory assessments of their anticoagulant effect ex vivo.

Keywords

novel direct oral anticoagulants - dabigatran - rivaroxaban - apixaban - antibiotics - interaction
 

  • References

  • 1 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G ; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-88S
    CrossrefPubMedGoogle Scholar
  • 2 Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype?. Clin Chem Lab Med 2009; 47 (5) 503-515
    CrossrefPubMedGoogle Scholar
  • 3 Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012; 22 (3) 329-341
    PubMedGoogle Scholar
  • 4 Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013; 2013: 640723
    PubMedGoogle Scholar
  • 5 Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2014; 100 (5) 396-405
    CrossrefPubMedGoogle Scholar
  • 6 Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012; 38 (1) 7-15
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). Clin Chem Lab Med 2012; 50 (12) 2137-2140
    PubMedGoogle Scholar
  • 8 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31 (3) 326-343
    CrossrefPubMedGoogle Scholar
  • 9 Holbrook AM, Pereira JA, Labiris R , et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165 (10) 1095-1106
    CrossrefPubMedGoogle Scholar
  • 10 Ghaswalla PK, Harpe SE, Tassone D, Slattum PW. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic. Am J Geriatr Pharmacother 2012; 10 (6) 352-360
    CrossrefPubMedGoogle Scholar
  • 11 Heidbuchel H, Verhamme P, Alings M , et al; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (5) 625-651
    CrossrefPubMedGoogle Scholar
  • 12 US Food and Drug Administration. Pradaxa. Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 13 US Food and Drug Administration. Xarelto. Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 14 US Food and Drug Administration. Eliquis. Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 15 US Food and Drug Administration Advisory Committee Briefing Document: Dabigatran etetexilate. Boehringer Ingelheim Pharmaceuticals, Inc. August 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterial/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 16 Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?. Ann Pharmacother 2013; 47 (11) 1478-1487
    CrossrefPubMedGoogle Scholar
  • 17 Härtter S, Koenen-Bergmann M, Sharma A , et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012; 74 (3) 490-500
    CrossrefPubMedGoogle Scholar
  • 18 Delavenne X, Ollier E, Basset T , et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76 (1) 107-113
    CrossrefPubMedGoogle Scholar
  • 19 Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76 (3) 455-466
    CrossrefPubMedGoogle Scholar
  • 20 Zhang D, He K, Herbst JJ , et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos 2013; 41 (4) 827-835
    CrossrefPubMedGoogle Scholar
  • 21 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
    CrossrefPubMedGoogle Scholar
  • 22 Majerus PW, Broze GJ, Miletich JP , et al. Anticoagulant thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, , eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996: 1347-351
    Google Scholar
  • 23 Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L ; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation—sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75 (4) 800-805
    CrossrefPubMedGoogle Scholar
  • 24 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50 (10) 675-686
    CrossrefPubMedGoogle Scholar
  • 27 Harenberg J, Kraemer S, Du S , et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014; 40 (1) 129-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Cuker A. Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Hemost 2012; 38 (6) 593-599
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39 (2) 117-126
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013; 39 (2) 147-152
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013; 39 (7) 840-846
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Lippi G, Ardissino D, Quintavalla R, Cervellin G. Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolysis 2014; ;doi: 10.1007/s11239-014-1082-5
    PubMedGoogle Scholar
  • 34 Favaloro EJ, Bonar R, Butler J, Marsden K. Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology 2013; 45 (4) 435-437
    CrossrefPubMedGoogle Scholar
  • 35 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49 (5) 755-757
    CrossrefPubMedGoogle Scholar
  • 36 US Food and Drug Administration Advisory. Committee Briefing Document: Dabigatran etexilate. Boehringer Ingelheim Pharmaceuticals, Inc.
    PubMedGoogle Scholar
  • 37 eHealthMe. Review: Pradaxa and Amoxicillin drug interactions. Available at: http://www.ehealthme.com/drug-interactions/Pradaxa-and-Amoxicillin . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 38 eHealthMe. Review: Pradaxa and Ceftriaxone drug interactions. Available at: http://www.ehealthme.com/drug-interactions/ceftriaxone-and-pradaxa . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 39 eHealthMe. Review: Pradaxa and Metronidazole drug interactions. Available at: http://www.ehealthme.com/drug-interactions/pradaxa-and-metronidazole . Accessed: March 11, 2014
    PubMedGoogle Scholar
  • 40 Bohm NM, Crosby B. Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. Ann Pharmacother 2012; 46 (7-8) e19
    CrossrefPubMedGoogle Scholar
  • 41 Holt RK, Anderson EA, Cantrell MA, Shaw RF, Egge JA. Preemptive dose reduction of warfarin in patients initiating metronidazole. Drug Metabol Drug Interact 2010; 25 (1-4) 35-39
    PubMedGoogle Scholar
  • 42 Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. World J Gastroenterol 2005; 11 (18) 2720-2725
    CrossrefPubMedGoogle Scholar
  • 43 Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered. Ann Pharmacother 2007; 41 (4) 653-658
    CrossrefPubMedGoogle Scholar
  • 44 Kim KA, Park JY. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol 2010; 66 (7) 721-725
    CrossrefPubMedGoogle Scholar
  • 45 Fung E, Patsopoulos NA, Belknap SM , et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost 2012; 38 (8) 893-904
    Article in Thieme ConnectPubMedGoogle Scholar